Nama's AI scorecard currently rates ICON Public Hold (4.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ICLR's P/E ratio?

ICON Public trades at a trailing price-to-earnings ratio of 18.5.

When does ICLR report earnings?

ICON Public's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $2.82.

What is the ICLR price target?

The median analyst price target from 17 analysts is $230.00, with a range of $180.00 – $268.00.

Is ICLR Shariah compliant?

Nama's AAOIFI-style screen reads ICON Public as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

ICON Public (ICLR)

Healthcare · Diagnostics Research · NASDAQ

ICON Public (ICLR) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $15.34B, a trailing price-to-earnings ratio of 18.5 and a free-cash-flow yield of 5.0%. Over the most recent reported fiscal year, revenue grew 0.8% and free cash flow per share fell 29.4%. Nama's AI scorecard rates it Hold, 4.6 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 4.6/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +2.5% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-41.1%

How far the last close sits under the highest price of the past five years.

Market cap	$15.34B
Trailing P/E	18.5
Price / book	1.7
Price / sales	1.9
FCF yield	5.0%
Dividend yield	—
Gross margin	24.3%
Operating margin	10.1%
Net margin	0.2%
Revenue growth (YoY)	+0.8%
Revenue growth (3-yr annual)	+2.1%
EPS growth (YoY)	—
FCF/share growth (YoY)	-29.4%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

ICLR earnings

Next report: Feb 17, 2027 (Q4 2026, EPS estimate $2.82). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 27, 2026	$2.66	$2.63	+1.1%	$2.02B
Q2 2026	Jul 29, 2026	$2.56	$2.52	+1.6%	$2.06B
Q1 2026	May 27, 2026	$2.52	$3.11	-19.0%	$2.03B
Q3 2025	Oct 22, 2025	$3.31	$3.28	+0.9%	$2.08B

ICLR analyst price target

Median target $230.00 from 17 analysts, ranging $180.00 – $268.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live ICLR data on Nama Insights →

Recent Congressional trades

ICON Public trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Kevin Hern	House	Sell	$15,001 - $50,000	Sep 1, 2026
Kevin Hern	House	Sell	$100,001 - $250,000	Apr 3, 2026
Julia Letlow	House	Sell	$1,001 - $15,000	Mar 12, 2026

ICLR FAQ

Is ICLR a buy?: Nama's AI scorecard currently rates ICON Public Hold (4.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ICLR's P/E ratio?: ICON Public trades at a trailing price-to-earnings ratio of 18.5.
When does ICLR report earnings?: ICON Public's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $2.82.
What is the ICLR price target?: The median analyst price target from 17 analysts is $230.00, with a range of $180.00 – $268.00.
Is ICLR Shariah compliant?: Nama's AAOIFI-style screen reads ICON Public as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.